Home -
General Info -
Treatments -
Search -
Index -
Email
DMARDs and Biologics
Disease-Modifying Anti-Rheumatic Drugs (DMARDs) are a class of drugs which can stop the progression of rheumatoid and psoriatic arthritis. These drugs often have serious side effects, but given the importance of not letting arthritis damage joints, the possible complications are often acceptable (especially when the choice is between being able to move
and not moving). These drugs may, in some cases of severe psoriasis with or without arthritis, also be useful
in reducing the skin symptoms of the disease.
Biologics are drugs (or devices) which are produced by living organisms. These are, these days, typically proteins. This area of drug research is where most of the psoriasis drugs under development are coming from. Creating specialized proteins which interfere with specific parts of the human immune system suspected to play a role in creating psoriasis symptoms.
Reviewed Treatments and Information:
Unreviewed Treatments and Information:
- ABX-IL8 (made by Abgenix)
- AmeviveTM (alefacept, LFA3TIP - made by Biogen)
- May 25, 1999 Press Release
- Release delayed until at least 2003
- Psoriasis Drugs Prepare to Go Head-to-Head (June 15, 2001)
- Liquent Technology Speeds International Registration Filing for Promising New Psoriasis Therapy (August 22, 2001)
- Mixed Ending to Stocks' Rough Day (June 14, 2002)
- New Psoriasis Drug Available (January 31, 2003)
- Biogen volatile in after-hours (June 13, 2002)
- Specialty Drug Distribution
(July 16, 2002)
- Drug Distribution Digest
(October 4, 2002)
- FDA Committee Endorses New Psoriasis Treatment (May 24, 2002)
- Biogen recibe la calificación Respuesta Completa de la FDA para la aplicación de AMEVIVE (alefacept) (June 14, 2002)
- Biogen presenta una solicitud para la aprobación de AMEVIVE (alefacept) a comienzos de 2003 (September 13, 2002)
- Biogen's SEC Filings
- Nursing Spectrum (March 13, 2003)
- Psoriasis Goes Prime Time
(February, 2003)
- Sagitta Healthcare Fund
- FDA: Biogen's Amevive carries infection risk (May 22, 2002)
- Lou Dobbs Moneyline (May 23, 2002)
- New Psoriasis Drug Available (January 31, 2003)
- New Psoriasis Drugs Seem Promising In Tests (March 9, 2001)
- New Treatments on the Horizon for Psoriasis
- Psoriasis Relief, at a Price (March 4, 2003)
- Biogen Stock
- FDA OKs Unique New Psoriasis Treatment (January 31, 2003)
- Cincinatti Enquirer Business Highlights (May 27, 2002)
- USACHPPM Health Information Operations Update
(February 7, 2003)
- Anti-CD4:
- Anti-IL2R (Simulect®, basiliximab)
- Arthritis Drugs Provide Psoriasis Relief on WebMD
- Biologic Therapy for Psoriasis (abstract) from the Archives of Dermatology
- Biologics Approved for Treatment of Psoriasis
- Biospace News: Psoriasis
- Enbrel (etanercept - made by Immunex Corporation, marketed by Amgen and Wyeth Pharmaceuticals)
- Fusion Proteins
- The Heartbreak of Psoriasis
- HU1124
- HumaT4 (Made by Intracel)
- HuMax-CD4 (Made by Genmab A/S)
- HuMax-IL15 (Made by Genmab A/S)
- IDEC-114 (made by IDEC Pharmaceuticals)
- Immunoassays and Other Immunological Techniques Based Upon Antibodies
- ISIS 2302
- LFA-1 Antagonists:
- MEDI-507 (siplizumab - made by MedImmune)
- Monoclonals Get Slammed
- New Hope for the Heartbreak of Psoriasis
- No More Itching in N'Awlins
- P38 Kinase Inhibitors
- Psoriasis Drugs Prepare to Go Head-to-Head (June 15, 2001)
- Psoriasis Relief, at a Price
- RaptivaTM (efalizumab, anti-CD11a, used to be called Xanelim - made by Genentech and XOMA)
- Remicade® (infliximab - made by Centocor)
- Say Farewell to the Psoriasis Heartbreak
- Solid Gold Sales
- Xerecept® (hCRF, Neurobiological Technologies, Inc.)
- Zenapax® (anti-CD25, daclizumab - made by PDLI)
Created Prior to August 10, 1999.
Last Updated on September 1, 2003.
The information provided here is not medical advice. This is not a self-help web site. Seek professional advice before beginning, ending, or changing treatments for any disease or condition. See the Legal Info page for more information.
Copyright © 1999 by
Dave W.
